About this study
Langerhans cell histiocytosis (LCH) is a rare disease that causes too many Langerhans cells (a type of white blood cell) to grow. It is most common in children and young adults. LCH can affect many different parts of the body, including the bones, skin and lungs. It can damage these tissues and organs and also affect the pituitary gland. This gland makes hormones that control many body functions, such as growth.
Previous clinical trials have improved the treatment and care for children with LCH. However, some patients still do not respond to initial treatment. Others may respond to initial treatment but the disease comes back later. In this study, researchers want to tailor treatment, based on the extent and type of LCH patients have and how they respond to therapy. Participants will be divided into different groups, depending on the level of disease they have. Each group is called a stratum.
Eligibility overview
- Diagnosis of Langerhans cell histiocytosis
- Younger than 18 years old
- Meets inclusion criteria for the respective stratum